High-Risk, Advanced-Stage Hodgkin Lymphoma: The Impact of Combined Escalated BEACOPP and ABVD Treatment in Patients Who Rapidly Achieve Metabolic Complete Remission on Interim FDG-PET/CT Scan

By  

Acta Haematologica, Vol. 135, Iss. 3, 2015-11 ,pp. : 156-161

Karger

Access to resources Recommend Favorite

Frontline Therapy with Early Intensification and Autologous Stem Cell Transplantation versus Conventional Chemotherapy in Unselected High-Risk, Aggressive Non-Hodgkin’s Lymphoma Patients: A Prospective Randomized GEMOH Report

By  

Acta Haematologica, Vol. 115, Iss. 1-2, 2006-01 ,pp. : 15-21

Karger

Access to resources Recommend Favorite

Feasibility and efficacy of dose‐dense and dose‐intense ABVD for high‐risk patients with advanced Hodgkin lymphoma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 662-665

John Wiley & Sons Inc

Access to resources Recommend Favorite

Biomarker-guided de-escalation of empirical therapy is associated with lower risk for adverse outcomes

By Schuetz Philipp   Mueller Beat  

Intensive Care Medicine, Vol. 40, Iss. 1, 2014-01 ,pp. : 141-141

Springer Publishing Company

Access to resources Recommend Favorite

De-escalation of empirical therapy is associated with lower mortality in patients with severe sepsis and septic shock

By Garnacho-Montero J.   Gutiérrez-Pizarraya A.   Escoresca-Ortega A.   Corcia-Palomo Y.   Fernández-Delgado Esperanza   Herrera-Melero I.   Ortiz-Leyba C.   Márquez-Vácaro J.  

Intensive Care Medicine, Vol. 40, Iss. 1, 2014-01 ,pp. : 32-40

Springer Publishing Company

Access to resources Recommend Favorite